Table of Contents

company-logo

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.

Pieris Pharmaceuticals Dividend Announcement

• Pieris Pharmaceuticals does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Pieris Pharmaceuticals dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Pieris Pharmaceuticals Dividend History

Pieris Pharmaceuticals Dividend Yield

Pieris Pharmaceuticals current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Pieris Pharmaceuticals stock? Use our calculator to estimate your expected dividend yield:

Pieris Pharmaceuticals Financial Ratios

P/E ratio-1.37
PEG ratio-0.01
P/B ratio1.34
ROE-76.24%
Payout ratio0.00%
Current ratio4.82
Quick ratio4.82
Cash Ratio4.55

Pieris Pharmaceuticals Dividend FAQ

Does Pieris Pharmaceuticals stock pay dividends?
Pieris Pharmaceuticals does not currently pay dividends to its shareholders.
Has Pieris Pharmaceuticals ever paid a dividend?
No, Pieris Pharmaceuticals has no a history of paying dividends to its shareholders. Pieris Pharmaceuticals is not known for its dividend payments.
Why doesn't Pieris Pharmaceuticals pay dividends?
There are several potential reasons why Pieris Pharmaceuticals would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Pieris Pharmaceuticals ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Pieris Pharmaceuticals has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Pieris Pharmaceuticals a dividend aristocrat?
Pieris Pharmaceuticals is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Pieris Pharmaceuticals a dividend king?
Pieris Pharmaceuticals is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Pieris Pharmaceuticals a dividend stock?
No, Pieris Pharmaceuticals is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Pieris Pharmaceuticals stocks?
To buy Pieris Pharmaceuticals you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Pieris Pharmaceuticals stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.